# Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

> **NCT04117945** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Academic and Community Cancer Research United** · enrollment: 22 (actual)

## Conditions studied

- BRAF V600E Negative
- KRAS Gene Mutation Negative
- Locally Advanced Unresectable Colorectal Adenocarcinoma
- Metastatic Colorectal Adenocarcinoma
- NRAS Gene Mutation Negative
- Stage III Colorectal Cancer AJCC v8
- Stage IIIA Colorectal Cancer AJCC v8
- Stage IIIB Colorectal Cancer AJCC v8
- Stage IIIC Colorectal Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVC Colorectal Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Cetuximab
- **DRUG:** Irinotecan
- **BIOLOGICAL:** Panitumumab
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT04117945
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-03
- **Primary completion:** 2023-09-05
- **Final completion:** 2025-03-31
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04117945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04117945, "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04117945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*